168 related articles for article (PubMed ID: 35122589)
1. Germline Cancer Testing in Unselected Patients with Gastric and Esophageal Cancers: A Multi-center Prospective Study.
Uson PLS; Kunze KL; Golafshar MA; Botrus G; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Kahn A; Klint M; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T; Samadder NJ
Dig Dis Sci; 2022 Nov; 67(11):5107-5115. PubMed ID: 35122589
[TBL] [Abstract][Full Text] [Related]
2. Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study.
Uson Junior PL; Kunze KL; Golafshar MA; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Barrus K; Mountjoy L; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T; Samadder NJ
Cancer Prev Res (Phila); 2022 Feb; 15(2):121-128. PubMed ID: 34782326
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
Samadder NJ; Riegert-Johnson D; Boardman L; Rhodes D; Wick M; Okuno S; Kunze KL; Golafshar M; Uson PLS; Mountjoy L; Ertz-Archambault N; Patel N; Rodriguez EA; Lizaola-Mayo B; Lehrer M; Thorpe CS; Yu NY; Esplin ED; Nussbaum RL; Sharp RR; Azevedo C; Klint M; Hager M; Macklin-Mantia S; Bryce AH; Bekaii-Saab TS; Sekulic A; Stewart AK
JAMA Oncol; 2021 Feb; 7(2):230-237. PubMed ID: 33126242
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study.
Uson PLS; Samadder NJ; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Kunze K; Golafshar M; Klint M; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T
Clin Transl Gastroenterol; 2021 Oct; 12(10):e00414. PubMed ID: 34620795
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer.
Ku GY; Kemel Y; Maron SB; Chou JF; Ravichandran V; Shameer Z; Maio A; Won ES; Kelsen DP; Ilson DH; Capanu M; Strong VE; Molena D; Sihag S; Jones DR; Coit DG; Tuvy Y; Cowie K; Solit DB; Schultz N; Hechtman JF; Offit K; Joseph V; Mandelker D; Janjigian YY; Stadler ZK
JAMA Netw Open; 2021 Jul; 4(7):e2114753. PubMed ID: 34251444
[TBL] [Abstract][Full Text] [Related]
6. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study.
Uson PLS; Riegert-Johnson D; Boardman L; Kisiel J; Mountjoy L; Patel N; Lizaola-Mayo B; Borad MJ; Ahn D; Sonbol MB; Jones J; Leighton JA; Gurudu S; Singh H; Klint M; Kunze KL; Golafshar MA; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab TS; Jewel Samadder N
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e508-e528. PubMed ID: 33857637
[TBL] [Abstract][Full Text] [Related]
7. Germline Genetic Testing in Unselected Squamous and Non-Squamous Head and Neck Cancers.
Brake DA; Idler BM; Kunze KL; Golafshar MA; Heald B; Young S; Klint M; Barrus K; Esplin ED; Nussbaum RL; Samadder NJ; Hinni ML; Chang BA
Laryngoscope; 2023 Dec; 133(12):3378-3388. PubMed ID: 37132629
[TBL] [Abstract][Full Text] [Related]
8. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
[TBL] [Abstract][Full Text] [Related]
9. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
[TBL] [Abstract][Full Text] [Related]
10. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
[TBL] [Abstract][Full Text] [Related]
11. Germline pathogenic variants in unselected Korean men with prostate cancer.
So MK; Ahn HK; Huh J; Kim KH
Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218
[TBL] [Abstract][Full Text] [Related]
12. Germline Testing of Patients With Non-small Cell Lung Cancers Demonstrating Incidentally Uncovered BRCA2 Apparent Pathogenic Germline Variants.
Sorscher S
Clin Lung Cancer; 2022 Nov; 23(7):e405-e407. PubMed ID: 35977876
[TBL] [Abstract][Full Text] [Related]
13. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
[TBL] [Abstract][Full Text] [Related]
14. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
[TBL] [Abstract][Full Text] [Related]
16. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
[TBL] [Abstract][Full Text] [Related]
17. Genetic testing by cancer site: stomach.
Chun N; Ford JM
Cancer J; 2012; 18(4):355-63. PubMed ID: 22846738
[TBL] [Abstract][Full Text] [Related]
18. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
[TBL] [Abstract][Full Text] [Related]
19. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
Lee K; Yoo C; Kim KP; Park KJ; Chang HM; Kim TW; Lee JL; Lee W; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
Invest New Drugs; 2018 Feb; 36(1):163-169. PubMed ID: 28782087
[TBL] [Abstract][Full Text] [Related]
20. Pathogenic Germline Mutations in Chinese Patients with Gastric Cancer Identified by Next-Generation Sequencing.
Zhou J; Zhao Z; Zhang Y; Bao C; Cui L; Cai S; Bai Y; Shen L; Zhang X
Oncology; 2020; 98(8):583-588. PubMed ID: 32521533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]